Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
24510 | 259 | 32.1 | 69% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IPRIFLAVONE | Author keyword | 106 | 74% | 31% | 79 |
2 | TAK 778 | Author keyword | 18 | 83% | 4% | 10 |
3 | ULMUS WALLICHIANA | Author keyword | 6 | 80% | 2% | 4 |
4 | PURMORPHAMINE | Author keyword | 5 | 45% | 3% | 9 |
5 | KCA 098 | Author keyword | 5 | 63% | 2% | 5 |
6 | ANABOL SKELETAL TARGETS HLTH ILLNESS AS | Address | 5 | 50% | 3% | 7 |
7 | OSTEOGENIC | Author keyword | 2 | 13% | 7% | 17 |
8 | FLAVONOID C GLUCOSIDE | Author keyword | 2 | 67% | 1% | 2 |
9 | PTEROSPERMUM ACERIFOLIUM | Author keyword | 2 | 67% | 1% | 2 |
10 | PHARMACEUT S 4 | Address | 1 | 100% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IPRIFLAVONE | 106 | 74% | 31% | 79 | Search IPRIFLAVONE | Search IPRIFLAVONE |
2 | TAK 778 | 18 | 83% | 4% | 10 | Search TAK+778 | Search TAK+778 |
3 | ULMUS WALLICHIANA | 6 | 80% | 2% | 4 | Search ULMUS+WALLICHIANA | Search ULMUS+WALLICHIANA |
4 | PURMORPHAMINE | 5 | 45% | 3% | 9 | Search PURMORPHAMINE | Search PURMORPHAMINE |
5 | KCA 098 | 5 | 63% | 2% | 5 | Search KCA+098 | Search KCA+098 |
6 | OSTEOGENIC | 2 | 13% | 7% | 17 | Search OSTEOGENIC | Search OSTEOGENIC |
7 | FLAVONOID C GLUCOSIDE | 2 | 67% | 1% | 2 | Search FLAVONOID+C+GLUCOSIDE | Search FLAVONOID+C+GLUCOSIDE |
8 | PTEROSPERMUM ACERIFOLIUM | 2 | 67% | 1% | 2 | Search PTEROSPERMUM+ACERIFOLIUM | Search PTEROSPERMUM+ACERIFOLIUM |
9 | VERTEBRAL BONE LOSS | 1 | 40% | 1% | 2 | Search VERTEBRAL+BONE+LOSS | Search VERTEBRAL+BONE+LOSS |
10 | APATITE AND WOLLASTONITE CONTAINING GLASS CERAMIC A W GC | 1 | 50% | 0% | 1 | Search APATITE++AND+WOLLASTONITE++CONTAINING+GLASS+CERAMIC+A+W+GC | Search APATITE++AND+WOLLASTONITE++CONTAINING+GLASS+CERAMIC+A+W+GC |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | OSSICLE ORGAN CULTURES | 21 | 90% | 3% | 9 |
2 | ULMUS WALLICHIANA PLANCHON | 6 | 80% | 2% | 4 |
3 | FORMATION STIMULANT | 6 | 100% | 2% | 4 |
4 | IPRIFLAVONE PREVENTS | 6 | 100% | 2% | 4 |
5 | IPRIFLAVONE | 4 | 25% | 5% | 14 |
6 | DIFFERENTIATION PROMOTING COMPOUND | 3 | 100% | 1% | 3 |
7 | DRILL HOLE INJURY | 2 | 44% | 2% | 4 |
8 | BONE ANABOLIC AGENT | 1 | 100% | 1% | 2 |
9 | DENSITY LOSS | 1 | 50% | 1% | 2 |
10 | TAK 778 | 1 | 100% | 1% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Alternative therapies for menopause | 2000 | 42 | 41 | 17% |
Anabolic agents and the bone morphogenetic protein pathway | 2007 | 24 | 249 | 8% |
Role of Phytochemicals in the Prevention of Menopausal Bone Loss: Evidence from In Vitro and In Vivo, Human Interventional and Pharmacokinetic Studies | 2009 | 14 | 176 | 12% |
Therapy for osteoporosis - Miscellaneous and experimental agents | 1998 | 5 | 74 | 19% |
Miscellaneous and experimental agents | 1997 | 11 | 78 | 18% |
The role of small molecules in musculoskeletal regeneration | 2012 | 8 | 154 | 6% |
Current and potential future drug treatments for osteoporosis | 1996 | 26 | 115 | 6% |
The role of small molecules in bone regeneration | 2013 | 1 | 91 | 4% |
Update in women's health | 2003 | 3 | 27 | 4% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANABOL SKELETAL TARGETS HLTH ILLNESS AS | 5 | 50% | 2.7% | 7 |
2 | PHARMACEUT S 4 | 1 | 100% | 0.8% | 2 |
3 | ADV DENT TREATMENT PERIODONTOLCHIYODA K | 1 | 50% | 0.4% | 1 |
4 | BONE ARTICULAR CARTILAGE UNIT | 1 | 50% | 0.4% | 1 |
5 | HOSP UNIV SAN JUAN ALICANTE | 1 | 50% | 0.4% | 1 |
6 | NUTRACEUT NUTRAGENOM UNIT | 1 | 50% | 0.4% | 1 |
7 | ODONTOGNATHOSTOMATOL CLIN | 1 | 50% | 0.4% | 1 |
8 | ORAL MAXILLO IAL SURG PERIODONTOL | 1 | 10% | 2.3% | 6 |
9 | YOUNGDEUNGPO GU | 1 | 25% | 0.8% | 2 |
10 | BIOMECH REHABIL MED LOCOMOTOR PARATUS | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000108888 | DRYNARIA FORTUNEI//DRYNARIAE RHIZOMA//DRYNARIA QUERCIFOLIA |
2 | 0.0000097372 | ISOFLAVONES//GENISTEIN//EQUOL |
3 | 0.0000089187 | ASAN FDN//DA 125//MED DIAGNOST PATHOL |
4 | 0.0000083752 | DIETARY CA RESTRICTION//ZURICH OSTEOPOROSIS GRP//1 ALPHA HYDROXYVITAMIN D 3 |
5 | 0.0000079373 | CALCITONIN//SALMON CALCITONIN//CALCITONIN RECEPTOR |
6 | 0.0000078850 | PL BENCH CORE//ANTIDIARRHEIC//DRIED PLUM |
7 | 0.0000072930 | BUTEA MONOSPERMA//BUTEA FRONDOSA//ACANTHACEA |
8 | 0.0000065763 | OSTEOPOROSIS INDUCTION//CHAIR SURG PATHOPHYSIOL//OST 6 OSTEOCARE |
9 | 0.0000061826 | AROMATASE DEFICIENCY//MALE OSTEOPOROSIS//INTEGRATED MED ENDOCRINOL METAB GERIATR |
10 | 0.0000060053 | MARROW FIBROBLASTS//OSTEOPROGENITORS//OSTEOBLASTIC MARKERS |